Testagen
Reproductive peptide bioregulator
Testagen (Reproductive peptide bioregulator) is a longevity & bioregulators research compound. Reproductive-tissue bioregulator — proposed to support testicular/reproductive cell function and steroidogenesis signaling.
Testagen quick facts
| Reported research dose | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~30 min |
| Forms | Injectable |
| Evidence level | Russian studies; limited |
Reproductive-tissue bioregulator — course-based, pairs with HPTA support. Aimed at testicular tissue rather than at the hormonal axis above it, which is the distinction people miss — it is not an alternative to HCG or enclomiphene. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, total and free testosterone, LH and FSH, before and at 3 months. Run it as an experiment you measure, not a protocol you trust.
How Testagen works
Reproductive-tissue bioregulator — proposed to support testicular/reproductive cell function and steroidogenesis signaling.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Testagen
Buy Testagen at Biolongevity Labs →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Testagen
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Sold for reproductive tissue support and used by people hoping for a testosterone effect. Reported experience does not support that framing — nobody publishes before-and-after hormone panels showing a meaningful shift.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- Lys-Glu-Asp-Gly — a defined tetrapeptide targeting testicular tissue, proposed to support steroidogenesis signaling.
- The shared claim across the Khavinson series: peptides this short are proposed to enter the cell nucleus and bind promoter regions of DNA, shifting tissue-specific gene expression.
- Total and free testosterone are the cheapest, most objective endpoints in this entire catalog. Any real effect would be trivially demonstrable on a standard panel. Treat the absence of such data as the finding it is.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Testagen actually does
Testagen is Lys-Glu-Asp-Gly. C17H29N5O9, 447.45 Da, isoelectric point 4.18, computed net charge about −1.06 at pH 7.4. Where that sequence comes from is worth 2 sentences, because on this shelf it is unusual. Several trade names in this family map to a sequence only by vendor consensus — no paper says Vesugen is Lys-Glu-Asp or that Livagen is Lys-Glu-Asp-Ala. Testagen's mapping is printed twice, in 2 unrelated fields. The 2011 nuclear-penetration study lists it among its labeled peptides as ‘testagen, Lys-Glu-Asp-Gly’ Fedoreyeva 2011, and a 2025 corrosion paper writes it out as H-Lys-Glu-Asp-Gly-OH Dobrițescu 2025. The least-marketed peptide in the catalog has the best-documented sequence in it.
And it is 1 of only 4 peptides in this family ever given a named DNA motif — the only 1 of the 4 sold for a reproductive organ. Fluorescein-labeled short peptides entered HeLa cell nuclei — cytoplasm, nucleus and nucleolus — and their binding to defined deoxyribooligonucleotides discriminated both base sequence and cytosine methylation state. Epithalon, testagen and pinealon preferentially bound CAG; bronchogen preferred CTG Fedoreyeva 2011. That is a real, specific, checkable biophysical result, and it is a great deal more than ‘proposed to bind promoter regions’.
Read the same sentence again for what it costs. The CAG preference is shared with 2 peptides sold for entirely different organs — the pineal gland and the brain. 3 molecules, 3 organ labels, 1 reported motif. Whatever assigns these products to tissues, on the group's own binding data it is not the DNA preference. The charge argument fails the same way: Lys-Glu-Asp-Gly, Cardiogen's Ala-Glu-Asp-Arg, Vesugen's Lys-Glu-Asp and Livagen's Lys-Glu-Asp-Ala all compute to the same isoelectric point of 4.18 and the same −1.06 net charge at blood pH, because each carries 1 basic residue against 2 acidic ones. 4 products, 4 organs, 1 electrostatic profile. Anything that distinguishes them has to be the shape of a side chain, and no published experiment has tested that.
The corrosion paper is not a joke, and it constrains the mechanism. Testagen was studied as a copper corrosion inhibitor in sodium chloride solution: 86% inhibition efficiency, adsorption fitting a Freundlich isotherm, and a standard free energy of adsorption of −30.86 kJ/mol, which the authors read as spontaneous, mixed physical and chemical adsorption driven by electrostatic and van der Waals contributions with some covalent character Dobrițescu 2025. Hold that against the DNA claim. A molecule that sticks avidly and spontaneously to a metal surface it has no evolutionary relationship with is behaving as a generic adsorbent. Recognition means discriminating; promiscuity is the opposite property, and the systematic motif search this school published for peptide binding to double-stranded DNA is precisely an argument about which structural features let a short peptide discriminate at all Kolchina 2019.
Cell, rodent, human — and where it stops
In cells. Human HeLa cells, peptide applied to the medium, fluorescein label: the molecule reaches the nucleus and the nucleolus, and in a cell-free assay it binds defined oligonucleotides with a stated preference for CAG Fedoreyeva 2011. That is the entire cell record under this name.
In rodents: nothing indexed. In humans: nothing. And here is the fact that says most about how this product is sold. Searched against NCBI PubTator3 on 4 September 2026, the only paper in PubMed with ‘Testagen’ in its title is about protecting copper from salt water Dobrițescu 2025. A reproductive bioregulator with a retail price and a dosing schedule has 1 title-level paper, and it is materials science.
Now the extrapolation, labeled as one, because it is the reason this page exists. CAG is the codon for glutamine, and a CAG tract inside an exon is a polyglutamine tract. The most reproductively consequential CAG tract in the human genome sits in exon 1 of the androgen receptor, and its length is a graded modifier of receptor function: short tracts make a more transcriptionally active receptor, long ones a less active one. That is not speculation and it has been measured at population scale. In 1,324 young men from 5 Russian cities, median age 23, the AR CAG repeat ranged from 6 to 39 with a median of 23; men with normal semen quality averaged 23.2 repeats against 23.9 in men with impaired semen quality; and those in the long category (CAG ≥ 25) had lower total sperm count, sperm concentration, progressive motility and normal morphology than the short category (CAG ≤ 19), with hormone levels largely unchanged and the effect varying by ethnic group Osadchuk 2022.
So the chain is: a peptide sold for the testis is reported to prefer CAG, and the CAG tract that governs male reproductive function is one of the best-characterized polymorphisms in andrology. Nobody has connected those 2 sentences, including the people selling it. Be precise about what is not established: no experiment has shown Lys-Glu-Asp-Gly binding androgen receptor exon 1; no experiment in this family has shown that a peptide binding a CAG tract changes transcription of the gene containing it; and the 2011 binding was to short synthetic duplexes and to purified DNA, not to chromatinized genomic DNA inside a living cell. This is a hypothesis with an unusually clear experiment attached, not a finding.
The obstacles. (1) Delivery. 4 residues sits outside the di- and tripeptide substrate range described for PEPT1, PEPT2, LAT1 and LAT2 Khavinson 2022, and the 2023 assessment that scored 26 of these peptides against those carriers was molecular docking with no measured cellular uptake Khavinson 2023. (2) The motif is not private to this molecule Fedoreyeva 2011. (3) Nothing has been given to an animal under this name, so there is no species, route, dose or duration to report at the rodent step. (4) The outside view: the independent systematic review of this family covered 24 randomized trials over 2,245 participants on cognitive endpoints, with certainty rated low to very low and no reproductive arm Alsulaimani 2021.
Testagen pharmacokinetics — how much of it actually gets in
What degrades it, at the level of the bond. Lys-Glu-Asp-Gly carries a free N-terminal alpha-amino group on a lysine, and that is a good aminopeptidase N substrate — the enzyme is abundant on vascular endothelium, which is the surface a subcutaneous dose has to cross. Nothing on the molecule slows it: no acetyl cap, no C-terminal amide, no D-amino acid, no ring. For an unmodified 4-residue peptide the expected plasma residence is minutes, and there are 0 published pharmacokinetic measurements for it in any species to check that against. The Vault's ‘about 30 minutes’ is an expectation written as a measurement.
The charge problem, in this molecule's own numbers. At blood pH the peptide is a net anion, about −1.06. DNA's phosphate backbone is a polyanion. The single lysine cancels 1 of the 3 negative charges and leaves the molecule electrostatically repelled by the thing it is supposed to bind — which is exactly why the reported CAG preference has to come from base-edge contacts in a groove rather than from backbone attraction, and why the structural-motif question matters Kolchina 2019.
Oral versus injectable, and why this one is sold only as an injection. A swallowed tetrapeptide meets gastric acid at roughly pH 1.5–3.5, then pancreatic proteases, then brush-border peptidases, and the only named route across the enterocyte handles di- and tripeptides Khavinson 2022. No oral bioavailability figure has ever been published for this molecule, so the only honest move is to bound it: even at a generous 1 in 10 surviving, a capsule and a syringe would differ about 10-fold in delivered material, and nothing published could distinguish a 10-fold gap from a 1,000-fold one. Subcutaneous injection removes the gut and the first-pass liver and removes neither the plasma peptidases nor the question of whether any of it reaches a testis, for which there are 0 biodistribution studies.
A loss nobody has measured, and this molecule is the one with evidence for it. The corrosion study exists because Lys-Glu-Asp-Gly adsorbs spontaneously to a charged solid surface at −30.86 kJ/mol Dobrițescu 2025. Reconstituted peptide sits in glass, is drawn through a steel needle and is stored for days. Some fraction of a 2 mg vial is on the walls rather than in the syringe. Nobody has quantified it for any peptide in this catalog, and for this one there is a published adsorption free energy sitting there to predict it.
What would have to be true, and how you would know it was not
Four predictions. The first is the one that separates a real testicular effect from a coincidence, and almost nobody runs it correctly.
1. LH and FSH should not fall — and if testosterone rises while they stay flat, the testis is not the reason. This is negative feedback, and it is the whole logic of the hypothalamic axis: if a compound genuinely made Leydig cells produce more testosterone, the pituitary would see the extra androgen and drop LH. So the informative reading is the pair. Testosterone up with LH down means the signal came from above the testis; testosterone up with LH unchanged is far more likely to be assay noise, a different draw time or a different lab. Baseline total testosterone, free testosterone, SHBG and LH & FSH before 10am fasted, repeat at 3 months at the same lab at the same hour, and interpret them together or not at all.
2. The one test on this page actually worth ordering is not a test of the peptide. Androgen receptor sensitivity — the AR-CAG repeat length — is a one-time genetic test, fixed for life, and it explains why 2 men with identical testosterone feel completely different. In the 1,324-man cohort above, long repeats tracked with worse semen parameters while hormone levels barely moved Osadchuk 2022. If your reason for buying a testicular peptide is that your numbers look fine and you do not, this is the measurement that addresses it, and it costs one blood draw once.
3. PSA should not move, and a flat PSA is the expected result. Any compound producing a real androgenic effect would show it in an androgen-responsive tissue, and prostate-specific antigen is the cheapest window on that. Predicting no change is predicting the product does nothing measurable, which is the honest expectation from 0 human studies. A rising PSA during a course is a urology question, not a peptide question.
4. A semen analysis is the endpoint the claim deserves and the one nobody collects. Sperm concentration, total count, progressive motility and morphology to the WHO manual are the parameters the AR CAG work used Osadchuk 2022, they are the parameters a testicular claim implies, and spermatogenesis runs on roughly a 3-month cycle — so the retest window is 3 months after a course, not 3 weeks. The prediction is no change.
What nobody has tested yet
Five experiments. The first 2 are generated by the compound's own published binding data and neither has been attempted in 15 years.
1. Nobody has asked whether the CAG preference scales with repeat length. Synthesize androgen receptor exon-1 duplexes carrying 9, 22 and 44 CAG repeats plus a scrambled control, and run Lys-Glu-Asp-Gly against them by electrophoretic mobility shift and thermal denaturation — the same 2 assay formats this school has already used on peptide-DNA interactions Fedoreyeva 2011. If affinity rises with repeat number, the peptide reads a tract and the whole polyglutamine literature becomes relevant to it. If it does not, the reported preference is a local trinucleotide effect and the extrapolation on this page dies. Either result is worth publishing and neither has been sought.
2. Nobody has run the 3 CAG-preferring peptides against each other. Epithalon, pinealon and testagen were reported to share the preference Fedoreyeva 2011. Put all 3 on the same duplexes and measure dissociation constants. If they land within a factor of 2 of one another, the tissue assignments in this catalog have no basis in DNA binding, and that is the single most consequential negative result available in this field for the cost of an afternoon.
3. Nobody has stratified a course by receptor genotype. This is the only compound in the catalog whose own published mechanism predicts who should respond. Recruit men with short (CAG ≤ 19) and long (CAG ≥ 25) repeats, run the same course, and compare semen parameters and androgen markers at 3 months. It is the first genotype-stratified trial anyone could design here, and the design falls straight out of a 2011 binding assay.
4. Nobody has done a semen analysis before and after. 20 men, 2 samples each, a standard andrology lab. The claim is testicular and the measurement is routine.
5. Nobody has measured how much of the vial reaches the person. Reconstitute, hold 24 hours in glass and in polypropylene, assay by HPLC, and report the fraction remaining in solution. The published adsorption free energy for this exact peptide predicts a measurable loss Dobrițescu 2025, and the result would apply to every short peptide sold in a glass vial.
Testagen — its own safety story, not its class's
Three risks specific to this molecule, and one of them is generated by taking its own mechanism seriously.
1. If the CAG preference is real, the off-target list is a list of repeat-expansion disease genes. There is no reason a molecule with a trinucleotide preference would stop at the androgen receptor. Expanded CAG tracts are the mutation in Huntington disease, in several spinocerebellar ataxias, and in spinobulbar muscular atrophy — which is itself an androgen receptor CAG expansion, and presents with partial androgen insensitivity alongside motor neurone degeneration. Nothing published shows this peptide affecting any of them, and this page is not claiming it does. The point is narrower and harder to dismiss: ‘binds CAG’ names a class of loci, not a tissue, so the mechanism being true would make the product less organ-selective, not more. Anyone with a family history of a repeat-expansion disorder is the person with the least information here and the most riding on it.
2. The reproductive workup this replaces has treatable answers in it. Low testosterone with low or normal LH is secondary hypogonadism, and its standard workup includes prolactin, because a pituitary adenoma presents exactly this way, and iron studies, because hemochromatosis does too. Both are on this site's own panel, both are treatable, and both are missed by a peptide course. Low testosterone with high LH is primary testicular failure — the pattern a testicular peptide is marketed at and the one where a compound with 0 human studies is least likely to help. Ordering LH before ordering the peptide is the whole of the advice.
3. Men actively trying to conceive are the likeliest buyers and the least studied users. There are 0 semen analyses, 0 pregnancy outcomes and 0 reproductive toxicology studies published under this name in any species. A compound aimed at the testis with no fertility data is not thereby safe for fertility; it is unexamined, and those 2 are easy to confuse when a couple is 8 months into trying. With 0 clinical studies there has never been a setting in which an adverse event could have been recorded, so the 0 in the adverse-event column is a statement about the literature and not about the molecule.
Sources read for this page
- Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow) 2011;76(11):1210–1219 · PMID 22117547
- Dobrițescu A, et al. The Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces in Saline Environments: An Experimental and Computational Study. Molecules 2025;30(15):3141 · PMID 40807317
- Osadchuk L, Vasiliev G, Kleshchev M, Osadchuk A. Androgen Receptor Gene CAG Repeat Length Varies and Affects Semen Quality in an Ethnic-Specific Fashion in Young Men from Russia. International Journal of Molecular Sciences 2022;23(18):10594 · PMID 36142533
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Testagen — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Testagen — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Testagen moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Testagen in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Testagen
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Testagen — frequently asked questions
What is Testagen?
Testagen (Reproductive peptide bioregulator) is a longevity & bioregulators research compound. Reproductive-tissue bioregulator — proposed to support testicular/reproductive cell function and steroidogenesis signaling.
Is the full Testagen protocol on this page?
The reported research dose is on this page, along with how Testagen works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Testagen?
Testagen has an approximate half-life of ~30 min, which is part of what determines how often it's dosed.
What's the evidence behind Testagen?
Current evidence level: Russian studies; limited. Testagen is offered for research purposes only and is not an approved medicine.
Testagen inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Testagen is used for
Testagen appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Testagen is the upstream arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.